To further explore the ability of TMCO1 silencing to promote death in basal breast cancer cells, we performed cell death studies using other basal breast cancer cell lines that have been previously assessed in the context of Bcl-2 inhibition [39–41]. This evidence concerns the gene BCL2 and breast carcinoma.